The invention relates to modified oncolytic vaccinia virus vectors and their uses in cancer therapy. The vaccinia virus vectors comprise inactivating mutations in the thymidine kinase gene and in the vaccinia growth factor gene in addition to genes encoding marker or adjuvant proteins. A production method for the inventive vaccinia construct is also disclosed. The vaccinia virus vectors are useful for systemic and sequential therapeutic use for cancer.
